Bone News and Research

RSS

Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced the completion of patient follow-up in the Company's pivotal Phase III, Investigational Device Exemption (IDE) clinical trial with dermaPACE™ for the treatment of diabetic foot ulcers.

22 Sep 2010

Protein zyxin necessary for maintenance and repair of cell's cytoskeleton

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have discovered that a protein, zyxin, is necessary for the maintenance and repair of the cell's cytoskeleton, or internal framework, which serves as the muscle and bone of the cell. The research has implications for cancer, as well as other diseases, since alterations in the cytoskeleton are often associated with disease. The research was published in the Sep. 14, 2010, issue of the journal Developmental Cell.

22 Sep 2010

Zyxin protein is critical to maintain and repair internal framework

22 Sep 2010

Study links progressive osteoarthritis to IL-1Ra gene variations

Scientists from University of North Carolina at Chapel Hill School of Medicine and Interleukin Genetics, Inc. announced today findings from a large clinical study to evaluate the role played by genetic factors in the worsening of osteoarthritis.

22 Sep 2010

Fatty issues

In a new survey it was seen that too fat and too thin people suffer more from depressive moods. The Gallup-Healthways Well-Being Index published these findings it its September 17 issue and noted obese and underweight Americans are more stressed, worried, angry and sad than their overweight and normal weight friends.

22 Sep 2010

Impact of cancer treatment on cardiovascular function

For the past two decades, cancer therapy has become more sophisticated and effective, resulting in an ever-expanding group of long-term cancer survivors. There is also a growing awareness of the potentially negative effects of cancer treatment on the heart and the management of cardiac disease during and after cancer therapy.

22 Sep 2010

Amedica announces US Spine acquisition

Amedica Corporation (AC), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has acquired US Spine, a privately held, well-known medical device company focused on the development and commercialization of advanced spinal implant systems.

21 Sep 2010

New genes associated with osteoarthritis progression

21 Sep 2010

FDA grants orphan drug designation for MultiStem stem cell therapy

Athersys, Inc. announced today that MultiStem, Athersys' multipotent adult progenitor stem cell therapy, has been granted orphan drug designation by the U. S. Food and Drug Administration for the prevention of graft vs. host disease (GvHD).

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

Haskell completes St. John Broken Arrow Hospital

The Haskell Company announces it has completed construction on St. John Broken Arrow Hospital and its accompanying medical office building and medical campus in Broken Arrow, Okla., marking the largest design/build health care project in the company’s 45-year history.

21 Sep 2010

Orthovita publishes clinical data from IDE pilot studies

Orthovita, Inc., an orthobiologics and biosurgery company, is pleased to announce the publication of "Clinical Experience Using Cortoss for Treating Vertebral Compression Fractures with Vertebroplasty and Kyphoplasty" in the September 15, 2010 edition of Spine.

21 Sep 2010

Cook Medical expands Spectrum Turbo-Ject line of antibiotic impregnated PICCs for CRBSIs

Responding to increased demand for technology to help prevent potentially fatal catheter-related bloodstream infections (CRBSIs), Cook Medical has expanded its Spectrum Turbo-Ject line of antibiotic impregnated peripherally inserted central venous catheters (PICCs) to treat a wider range of patient needs. For the first time, the clinical benefits of minocycline and rifampin-impregnated PICCs, a critical component in eliminating 250,000 potentially fatal CRBSIs in the U.S. annually, are now available in 3 French single and 6 French triple lumen sizes.

21 Sep 2010

Public health at risk as Vitamin D evidence mounts

A group of prevention-focused healthcare organizations has expressed deep concern over recently-proposed restrictions to OHIP coverage of Vitamin D testing in the province. The proposed new legislation will delist OHIP insured Vitamin D testing for most Ontarians. Exceptions will be made for those with osteoporosis, malabsorption syndromes, and individuals taking medications that interfere with vitamin D absorption or metabolism.

21 Sep 2010

NQF endorses 8 outcome measures for pulmonary, cardiovascular conditions and care provided in ICU

To improve healthcare quality and give patients and providers more information about the results of care, the National Quality Forum (NQF) has endorsed eight outcome measures for pulmonary and cardiovascular conditions and care provided in the intensive care unit (ICU). This is the first in a set of patient outcome measures NQF is reviewing.

20 Sep 2010

Genzyme announces Japanese approval of Synvisc viscosupplement for OA knee pain relief

Genzyme Corporation announced today that Japan's Ministry of Health, Labour and Welfare has approved Synvisc® (hylan G-F 20; 3 x 2 mL), indicated for the treatment of osteoarthritis of the knee. Reimbursement has been obtained and publicized by Japan's Central Social Insurance Medical Council.

20 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

$Study on role of SurgiCase Orthopaedics in correction of compound wrist fractures$

Study on role of SurgiCase Orthopaedics in correction of compound wrist fractures

Materialise announced that it would lend its considerable expertise in virtual surgical planning to researcher Dr. J. B. Jupiter, Chief Hand and Upper Extremity Service at Massachusetts General Hospital. Through an AO funded, IRB approved study, Dr. Jupiter will use SurgiCase(R) Orthopaedics to explore the advantages of computer-assisted surgery, virtual 3D planning and intra-operative use of patient-specific surgical guides in osteotomies to correct compound wrist fractures-the first research project of its kind.

17 Sep 2010

Bone News and Research

Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

Protein zyxin necessary for maintenance and repair of cell's cytoskeleton

Zyxin protein is critical to maintain and repair internal framework

Study links progressive osteoarthritis to IL-1Ra gene variations

Fatty issues

Impact of cancer treatment on cardiovascular function

Amedica announces US Spine acquisition

New genes associated with osteoarthritis progression

FDA grants orphan drug designation for MultiStem stem cell therapy

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Haskell completes St. John Broken Arrow Hospital

Orthovita publishes clinical data from IDE pilot studies

Cook Medical expands Spectrum Turbo-Ject line of antibiotic impregnated PICCs for CRBSIs

Public health at risk as Vitamin D evidence mounts

NQF endorses 8 outcome measures for pulmonary, cardiovascular conditions and care provided in ICU

Genzyme announces Japanese approval of Synvisc viscosupplement for OA knee pain relief

Micromet initiates MT103 phase 2 trial in adult ALL patients

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Study on role of SurgiCase Orthopaedics in correction of compound wrist fractures

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News